Recommended Readings – Recent Articles
Clinical Trials Series [NEJM] by Janet Woodcock…Jeffrey Drazen
Assessing the Gold Standard — Lessons from the History of RCTs [NEJM] by Laura Bothwell…David S. Jones
The Changing Face of Clinical Trials: Integrating Randomized Comparative Effectiveness Research with Patient Care [NEJM] by Louis Fiore and Philip Lavori
Visualizations That Really Work [HBR] by Scott Berinato
Biomarker Tests for Molecularly Targeted Therapies — The Key to Unlocking Precision Medicine [NEJM] by Gary Lyman and Harold Moses
Reining in the supersized Phase I cancer trial [Nature Reviews Drug Discovery] by Asher Mullard
Pursuit of a perfect insulin [Nature Reviews Drug Discovery] by Alexander Zaykov, John Mayer & Richard DiMarchi
Ten years of anti-vascular endothelial growth factor therapy [Nature Reviews Drug Discovery] by Napoleone Ferrara & Anthony Adamis
Convertible visceral fat as a therapeutic target to curb obesity [Nature Reviews Drug Discovery] by Antonio Giordano, Andrea Frontini & Saverio Cinti
Drugging DNA repair [Science] by Stephen Jackson and Thomas Helleday
Global Oncology Trend Report – a Review of 2015 and Outlook to 2020 [IMS Health] by IMS Institute for Healthcare Informatics
Aligning statistical and scientific reasoning [Science] by Steven Goodman
Venture Capital and Its Discontents [WSJ] by Christopher Mims
Clinical Implications of Basic Research: Repressing Immunity in Autoimmune Disease [NEJM] by Jagadeesh Bayry
A Plan For Big Pharma Involvement In Superbug R&D [Forbes] by John LaMattina
Clinical Development Success Rates 2006-2015 [BIO] by BIO
Big Data: A Game Changer in Healthcare [Forbes] by Bernard Marr
Vacation Policy [AVC] by Fred Wilson
Open Vacation [Only Once] by Matt Blumberg
Our Experience with First-Time Biotech CEOs: Five Behaviors That Matter [Life Sci VC] by Bruce Booth
New York’s leading health systems differ on growth strategy [Politico] by Dan Goldberg
Leading Teams: Wicked-Problem Solvers [HBR] by Amy Edmondson
How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes [Bloomberg] by Benjamin Elgin and Robert Langreth
Coming of age: ten years of next-generation sequencing technologies [Nature Reviews Genetics] by Sara Goodwin, John McPherson and W. Richard McCombie
Big Pharma Innovation in Small Places [Fortune] by Jennifer Alsever
The U.S. spends more money on this medical condition than any other [The Washington Post] by Amy Ellis Nutt
From the analyst’s couch: Trends in clinical success rates [Nature Reviews Drug Discovery] by Katarzyna Smietana, Marcin Siatkowski & Martin Møller
Lessons from a Recovering Academic [Cell] by Michael Ehlers
Drug development: A healthy pipeline [Nature] by Branwen Morgan
Microbiome: Bacterial broadband [Nature] by Michael Eisenstein